The half-life of Melanotan in the body varies between its two primary forms, Melanotan I (afamelanotide) and Melanotan II, due to differences in their chemical structures and administration methods:
1.Melanotan I (Afamelanotide):
●Elimination Half-Life: Approximately 30–50 minutes when administered intravenously.
●Administration: Typically delivered via a subcutaneous implant, which provides sustained release over 30–60 days. This formulation maintains stable plasma levels despite the short elimination half-life, making it effective for conditions like erythropoietic protoporphyria.
2.Melanotan II:
●Elimination Half-Life: Around 1.5–3 hours after subcutaneous injection.
●Administration: Requires more frequent dosing (often daily or multiple times per day) due to its shorter half-life. Its cyclic heptapeptide structure enhances stability compared to linear peptides, but it is still metabolized relatively quickly.
Key Notes:
●The effective duration of action can extend beyond the elimination half-life, depending on the drug's mechanism, metabolites, or delivery method (e.g., implants for Melanotan I).
●Individual factors like metabolism, kidney function, and injection site may influence half-life variability.
Always consult clinical guidelines or a healthcare provider for dosing and safety information, as Melanotan compounds are not FDA-approved for cosmetic use and carry potential risks.
